PI-RADS v2 is a Strong Prognostic Marker for Adverse Outcomes in Prostate Cancer

Tolou Shadbahr, MSc[1]; Juho Pylväläinen, MD[2]; Juho Eineluoto, MD, PhD[1,3]; Alessio Moro, MSc[4,5]; Oleg Kerro, MD[3]; Anu Kenttämies, MD, PhD[2]; Eugen Czeizler, PhD[6]; Teemu J Murtola, MD[4,7]; Hyon-Jung Kim-Ollila, PhD[8]; Phillippe Puech, MD, PhD,[9]; Jonathan Olivier, MD, PhD[10]; Arnauld Villers, MD, PhD[11]; Jaakko Peltonen, PhD[12]; Matti Nykter, PhD[4]; Jing Tang, PhD[1,13]; Tuomas Mirtti, MD, PhD[1,14,15,16]; Teemu D. Laajala, PhD[1,15,17]§; Antti S. Rannikko, MD, PhD[1,3,15]§,*

1) Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

2) Department of Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

3) Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

4) Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.

5) Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.

6) National Institute for Research and Development in Biological Sciences, Bucharest, Romania.

7) Department of Urology, Tampere University Hospital and Tays Cancer Centre Tampere, Finland.

8) Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.

9) Genitourinary Imaging Department, CHU Lille, Lille, France.

10) Department of Urology, University of Lille, Lille, France.

11) Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France.

12) Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.

13) Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.

14) Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

15) iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

16) Finnish Cancer Institute, Helsinki, Finland

17) Department of Mathematics and Statistics, University of Turku, Turku, Finland

§ = shared senior authorship; * = corresponding author

Corresponding Author: Antti Rannikko, MD, PhD, Research Program in Systems Oncology and Department of Urology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. P.O. Box 63, FI-00014 University of Helsinki (antti.rannikko@hus.fi)

Abstract

Importance

Magnetic Resonance Imaging (MRI) coupled with Prostate Imaging-Reporting and Data System (PI-RADS) provides a standardized scoring system for assessing clinical significance of prostate cancer (PCa). However, the association between PI-RADS scores and key clinical end-points remains underexplored due to limited follow-up data.

Objective

To evaluate the association of PI-RADS with prostate cancer-specific mortality (PCSM), overall survival (OS), metastasis-free survival (MFS), and biochemical recurrence (BCR) across multiple cohorts.

Design, Setting, Participants

A retrospective registry cohort was collected from Helsinki University Hospital (HUS) for men with clinical suspicion of PCa. HUS cohort included 4,674 men who underwent diagnostic MRI during the PI-RADS version 2 era (2015-2019, median follow-up [mFU] 5.0 years). Validation cohorts were gathered from Tampere University Hospital (n=1,474, 2016-2021, mFU 2.2 years) and Lille University Hospital (N=301, 2016-2024, mFU 6.2 years).

Exposures

Diagnostic MRI imaging was scored using PI-RADS v2.

Main outcomes and measures

Primary outcomes were PCSM, OS, MFS, and BCR. Secondary measures included clinical confounders, such as age, Grade Group (GG), and Charlson's Comorbidity Index (CCI).

Results

In the HUS cohort, 84 of 4,674 patients (1.7%) died of PCa, with 79 patients (94%) presenting with PI-RADS score 5. In multivariable Cox regression adjusted for clinical confounders, PI-RADS score 5 was significantly associated with PCSM (Hazard Ratio (HR) 18.4, 95% CI [6.62-51.1], p<0.001), along with biopsy GG 5 (HR 5.45 [1.82-16.3], p=0.002), CCI (HR 1.53 [1.42-1.7], p<0.001), and log2-PSA (HR 1.28 [1.11-1.5], p<0.001). Kaplan-Meier curves demonstrated negligible PCSM after negative MRI (PI-RADS score 0-2) (log-rank p<0.001). PI-RADS score 5 was associated with OS in both the Helsinki and Tampere cohorts (p<0.001) and MFS and BCR in the Lille cohort (p<0.001).

Conclusion and relevance

PI-RADS score 5 is strongly associated with an increased risk of PCSM and other clinically relevant outcomes. Conversely, a non-suspicious MRI presents a negligible risk of adverse outcomes. These findings support the use of MRI for risk stratification in PCa.

Introduction

Prostate cancer (PCa) is the second most frequently diagnosed malignancy in men and fifth cause of death in men globally.[1] Prostate-specific antigen (PSA) testing and transrectal ultrasound (TRUS) guided biopsy are widely used diagnostic tools that have been shown to reduce prostate cancer-specific mortality (PCSM) in screening settings. However, these diagnostic pathways have also contributed to overdiagnosis and overtreatment.[2] These challenges can be mitigated through the adoption of MRI-based diagnostics combined with the standardized Prostate Imaging Reporting and Data System (PI-RADS).[3–12]

MRI-based diagnostic approaches (both MRI-targeted biopsies and MRI imaging) have demonstrated superior accuracy in detecting high-grade cancers compared to systematic biopsy, both in screening contexts [13–15] and in cases of clinical suspicion.[10,16] Epidemiological [17,18], histopathological [19,20], and genetic [21,22] studies suggest that MRI-invisible lesions may be biologically less aggressive than MRI-visible lesions of the same grade. However, Long-term, real-world validation of PI-RADS scoring has been limited, as clinical adoption only began in 2012 for PI-RADS version 1[3] and in 2015 for version 2 (v2)[4].

PI-RADS standardizes the acquisition of prostate MRI images, their interpretation, and reporting of their findings. Early studies have linked positive MRI findings (PI-RADS scores 3 to 5) with an increased risk of clinically significant PCa (csPCa), a greater likelihood of positive surgical margins, and a higher risk of biochemical recurrence (BCR) after radical prostatectomy (RP).[6,19,23–29] Despite these advancements, recent work by Wibmer et al. highlighted a gap in connecting MRI findings with the strongest clinical end-points, such as PCSM [24,30]. To address the lack of PI-RADS era cohorts, Wibmer and colleagues retrospectively assigned PI-RADS scores to pre-PI-RADS era MRIs and concluded that MRI findings are associated with long-term clinicopathologic outcomes. However, these retrospective scores were based on anatomical sequences, excluding key PI-RADS functional sequences such as Diffusion-Weighted Imaging (DWI), which are crucial for contemporary MRI in clinical practice.

This multicohort study evaluates the association of PI-RADS v2 with key clinical outcomes in prostate cancer, including PCSM, overall survival (OS), metastasis-free survival (MFS), and BCR.

Materials and Methods

All patients in this study underwent multiparametric MRI (mpMRI) during the PI-RADS v2 era. Table 1 summarizes all cohorts and their key variables.

Helsinki University Hospital Exploratory Cohort

The Helsinki-Uusimaa Hospital District encompasses the largest tertiary care patient population in Finland. Registries from Helsinki University Hospital (HUS) were utilized to integrate MRI imaging data, clinical variables, and adverse outcomes. The study cohort included men undergoing diagnostic evaluation for suspected prostate cancer (Figure 1A). Patient exclusion criteria are outlined in Supplementary Figure S1.

A total of 4,674 patients were included, with a median follow-up time of 5.0 years (IQR 4.2-5.8). Follow-up began on the date of the first MRI recorded in the HUS electronic health record (EHR) system (HUS Acamedic). mpMRIs were performed at HUS between 2015 and 2019, following the adoption of the PI-RADS version 2, with imaging protocols described in Pylväläinen et al.[18] Radiologists with over five years of experience in prostate MRI interpreted the images according to the European Society of Urogenital Radiology (ESUR) PI-RADS v2 guidelines.

Patients with metastatic disease at baseline or with biopsy results recorded outside a one-year window from the first MRI were excluded (Supplementary Figure S1). The ISUP Grade Group (GG) of biopsies was extracted from semi-structured and free-form pathological statements. Among patients with unknown biopsy status, the majority were confirmed to have negative MRI findings (Supplementary Table S1).

Table 2 provides a comprehensive overview of HUS cohort variables stratified by PI-RADS scores. The primary outcomes included PI-RADS scores recorded during the version 2 era and clinical end-points such as PCSM, OS, MFS, and BCR. Cause of death was retrieved from the national Statistics Finland registry, which has excellent agreement (kappa 0.95), with 96% sensitivity and 99% specificity for identifying prostate cancer deaths.[31] Secondary measurements included clinical confounders relevant to PCa, such as PSA levels, patient age, biopsy GGs, known interventions, and comorbidities (Table 1).

PSA levels were obtained from the hospital's laboratory services (HUSLAB). For patients with multiple PSA measurements, the most recent value at the time of the MRI was selected. PSA values were missing for 779 patients and were imputed using multiple imputation by chained equations (MICE). Quan's adjusted Charlson's Comorbidity Index (CCI) was calculated using all ICD-10 diagnosis codes available in the EHR database up to the time of MRI, with an additional three-month window. The prostate cancer diagnosis code (C61) was excluded from the CCI calculations to assess the comorbidity burden independent of confirmed prostate cancer diagnosis.

Metastasis status was not categorically reported but was collected for patients who underwent bone scans or PSMA PET scans at HUS. Data were crosslinked to two separate ongoing studies. Metastasis screening is performed at clinician's discretion, typically in men with higher risk disease. Metastatic disease (M1) was defined as at least one positive lesion in a lymph node, soft tissue, or bone, similar to Lille cohort. Among 864 patients in the HUS cohort who underwent bone or PET scans due to suspected metastases, 741 were confirmed metastasis-free (N0M0), and 123 patients were identified as having metastatic disease. Further details regarding metastasis data collection are provided in the supplementary material.

The use of registry data for this study was approved by the HUS Institutional Board (HUS/333/2019). The research adhered to the World Medical Association's Declaration of Helsinki on good research practices. As this study was based on registry data, no explicit patient consent was required.

Tampere University Hospital and Lille University Hospital Validation Cohorts

Pirkanmaa Hospital District (Tampere University Hospital) is the second-largest hospital district in Finland. Between 2000 and 2021, 17,125 men were diagnosed with prostate cancer (ICD-10 code C61). Their PI-RADS scores, PSA values, and biopsy GGs were retrospectively collected from the Tampere University Hospital EHR system (Figure 1A). Patients were excluded if they had missing birthdate, or missing follow-up information (e.g., any-cause death) and follow-up of less than 28 days post-MRI. After applying these criteria, 1,474 patients were included in the Tampere cohort, with a median follow-up time of 2.2 years (IQR 1.1-3.4). The recorded endpoint was any-cause mortality.

The Lille University Hospital cohort originally included 713 men who underwent MRI between 2007 and 2022. A subset of 301 patients with PI-RADS v2 MRI reports was selected, restricted to those who underwent MRI imaging after 2015 (Figure 1A). The median follow-up time was 6.2

years (IQR 4.8-7.4). All patients in the Lille cohort underwent RP, and the primary endpoints included metastasis-free survival and biochemical recurrence-free survival. For more details on the Lille cohort and its selection criteria, refer to Bommelaere et al.[32] Additional details on the Tampere and Lille cohorts are provided in the Supplementary Material.

Statistical analyses

Statistical analyses, visualizations, and data processing were conducted using R Statistical Software (R Core Team, 2024; Vienna, Austria; version 4.4.0 and newer) and Python (Python Software Foundation; version 3.8.0 and newer). Imputation was performed using the MICE R-package (version 3.16.0)[33] and CCI was calculated using comorbidity R-package (v1.1.0). Kaplan-Meier (KM) curves were generated using R-packages survival (v3.8.3), ggsurvfit (v1.1.0), and survminer (v0.5.0)s. Competing risks were illustrated by cumulative proportions over time, categorized by patient statuses alive, non-PCa death, PCa-specific death, and censoring (lost to follow-up). These visualizations were inspired by Albertsen et al.[34] but included censoring to account for incomplete event follow-up data. Fine-Grey competing risk models were fit using tidycmprsk R package (v1.1.0). Multivariable Cox proportional hazards models were used to evaluate the association between PI-RADS scores and disease endpoints, adjusting for clinical confounders including patient's age at MRI, PSA, biopsy GG, interventions, and CCI. Hazard Ratios (HRs), 95% Confidence Intervals (CIs), and p-values were reported, with $p<0.05$ considered statistically significant in all analyses.

Results

Association Between PI-RADS Scores and Clinically Relevant Outcomes

We first evaluated the association between PIRADS scores and clinically relevant outcomes in the HUS cohort. Kaplan-Meier analysis revealed that men with a PI-RADS score of 5 had a significantly higher risk of PCSM, all-cause mortality, and metastasis occurrence (Figure 1B; $p<0.001$). After a median follow-up of 2.8 years, 3% of men with PI-RADS 5 experienced PCSM. A similar statistically significant trend was observed for PI-RADS 5 in association with both OS and MFS.

When PI-RADS 5 was combined with GG 5, representing very high-risk aggressive prostate cancer, PCSM increased to 13% (32/241) within four years (Supplementary Figure S2; $p<0.001$).

In the Tampere validation cohort, PI-RADS 5 was significantly associated with OS trends (Figure 1C; $p<0.05$). Similarly, in the Lille validation cohort of RP-treated men, PI-RADS 5 was significantly associated with both MFS and BCR (Figure 1D; $p<0.005$). An additional pre-PI-RADS era cohort from Helsinki, with a median follow-up of 10.2 years, demonstrated a significant difference in PCSM risk between negative versus positive MRI findings (Supplementary Figure S3; $p<0.001$).

Competing risk analysis

Given the high competing mortality risk in men with prostate cancer, we explored competing risks during follow-up. We plotted patient proportions over time, categorized as alive, censored, PCa-specific death, and non-PCa death, over a six-year-follow period in the HUS cohort (Figure 2). Both PI-RADS and biopsy GG were associated with PCSM. Men with PI-RADS 5 lesions had a significantly higher risk of PCSM compared to men with PI-RADS 0-4. Furthermore, age was associated with an increasing trend in non-PCa mortality, although the proportion of PCa-specific deaths remained relatively consistent across age groups (Supplementary Figure S4).

To assess competing risks, we fitted Fine-Gray model for PCa-specific death and non-PCa death, treating them as competing endpoints for PI-RADS and biopsy GG (Supplementary Table S2). PI-RADS score 5 was highly associated with PCa-death (HR 75.1; CI 95% [10.2, 554], p<0.001) together with GG 5 (HR 10.1 [3.63, 28.1], p<0.001) and GG Unknown (HR 3.50 [1.19, 10.3], p=0.023). PI-RADS score 3 or 4 (HR 1.55 [1.15, 2.07], p=0.004) and PI-RADS 5 (HR 2.03 [1.49, 2.79], p<0.001) and GG Unknown (HR 1.60 [1.20, 2.13], p=0.002) were also associated with elevated risk of non-PCa death, albeit with more modest hazard ratios.

Multivariable Analysis Adjusting for Clinical Confounders

Next, we tested whether PI-RADS remained a significant predictor of clinically relevant outcomes after adjusting for clinical confounders in the HUS cohort. We performed multivariable Cox regression analysis to assess whether PI-RADS score 5 was still significantly associated with PCSM (Figure 3A) and OS (Figure 3B). For PCSM (Figure 3A), PI-RADS score 5 remained a strong prognostic indicator (HR 18.40; 95% CI [6.62-51.1], p<0.001), along with log2-transformed PSA (HR 1.28 [1.11-1.5], p<0.001), GG 5 (HR 5.45 [1.83-16.3], p=0.002), and CCI (HR 1.53 [1.42-1.7], p<0.001). Notably, immediate curative-intent interventions (RP, RT) were not significant predictors of PCSM (HR 0.70 [0.36-1.4], p=0.284).

For OS (Figure 3B), PI-RADS 5 (HR 1.65 [1.30-2.1], p<0.001), log2-transformed PSA (HR 1.11 [1.03-1.2], p=0.006), GG 5 (HR 1.82 [1.27-2.6], p<0.001), and CCI (HR 1.45 [1.39-1.5], p<0.001) were significantly associated with an increased risk of death. As expected, age at MRI was also significantly associated with increased all-cause mortality (HR 1.07 [1.06-1.1], p<0.001). Additionally, an unknown biopsy status was linked to higher all-cause mortality (HR 1.52 [1.16-2.0], p=0.002), likely reflecting patient selection bias.

PI-RADS 5 and metastatic spread

Finally, to explore the relationship between PI-RADS 5 and metastatic spread, we analyzed their interaction in Cox models for PCSM (Figure 3C). Both PI-RADS and M-status were significant independent explanatory variables (p<0.05). However, their interaction was not statistically significant (p=0.991). This trend remained consistent even when biopsy GG was incorporated into the multivariable Cox model (Supplementary Figure S5). These findings suggest that PI-RADS 5 provides complementary prognostic information rather than merely serving as a surrogate marker for metastatic spread.

Discussion

Our main finding is that a PI-RADS score 5 is associated with a significantly elevated risk of prostate cancer-specific mortality. This association remains robust after adjusting for confounders and extends consistently to other critical clinical endpoints, including overall survival, metastasis-free survival, and biochemical recurrence across multiple cohorts. Conversely, our data suggests that a negative MRI is associated with a very low risk of adverse outcomes.

To our knowledge, this is the first study to directly assess PI-RADS scores at the time of diagnosis in relation to PCSM, particularly using the PI-RADS v2 era data, where prostate MRI has become a standard pre-biopsy triaging tool for men suspected of having localized or locally advanced non-metastatic prostate cancer.

We specifically focused on PI-RADS version 2, as it best represents current guideline recommendations for MRI as a pre-biopsy triage test. However, we acknowledge that this choice

limits the follow-up duration, as PI-RADS and PI-RADS version 2 recommendations were introduced in 2012 and 2015, respectively. To address this, we extended our analysis to a pre-PI-RADS era cohort, where MRI results were classified as either positive or negative, rather than using the five-tier PI-RADS system. Our findings were consistent: men with a positive MRI had a significantly higher risk of PCSM and other adverse clinical endpoints, while men with a negative MRI had a negligible risk.

Our results align with the findings by Wibmer et al., who analyzed a cohort with T2-weighted MRI images in pre-PI-RADS era and reported that MRI findings correlated with PCSM [24,30]. Interestingly, these data suggest that not only contemporary multiparametric or biparametric MRI - incorporating diffusion-weighted imaging and possible dynamic contrast-enhanced imaging - but also anatomical sequences alone may contain some prognostic biomarkers. Future studies should further explore the prognostic value of prostate MRI, integrating both anatomical and functional imaging sequences to enhance risk stratification and deepen our understanding of prostate cancer biology.

We validated our findings in two independent external cohorts. In Tampere, Finland, we confirmed the association of PI-RADS 5 with OS in men with a confirmed prostate cancer diagnosis. The Lille cohort represents a contemporary PI-RADS v2 era cohort, consisting of healthy men fit for surgery, diagnosed with localised or locally advanced non-metastatic prostate cancer, and treated with radical prostatectomy. As expected, these surgically treated men had better survival outcomes than our broader cohort, which included all men with non-metastatic prostate cancer. In the Lille cohort, we only observe two PCa-related deaths among 301 RP-treated patients despite a median follow-up of over six years. Nonetheless, PI-RADS remained a prognostic factor across both cohorts, particularly for MFS and BCR.

Our findings underscore that PI-RADS score 5 is a robust predictor of PCSM, additive to established prognostic markers such as biopsy GG and metastatic spread. Even after adjusting for these clinical confounders, the prognostic value of PI-RADS 5 remained statistically significant, highlighting its potential role as an independent imaging biomarker for risk stratification in prostate cancer management.

Interestingly, immediate curative-intent interventions (radical prostatectomy or radiation therapy) were not statistically significant predictors of PCSM in our multivariable Cox regression analysis. This result aligns with findings from the ProtecT trial[35], which reported no significant PCSM survival benefit between surgery and radiation therapy. However, when considering OS, expected confounders such as age and immediate interventions became statistically significant. This likely reflects selection bias, where healthier patients are more likely to receive curative treatment.

In clinical risk stratification, our findings may help identify a very high-risk group, such as GG 5 and PI-RADS 5, who may benefit from adjuvant or neoadjuvant therapies in addition to curative-intent treatment. For men with PI-RADS 5 but otherwise favorable clinical parameters on active surveillance, our data suggest that more intensive monitoring may be warranted. This is supported by recent findings by Peyrottes et al., who reported that while active surveillance remains feasible for PI-RADS 5 patients, these men have a higher likelihood of GG reclassification and earlier conversion to curative treatment.[36] Our findings also have direct implications for prostate cancer screening protocols. Men with PI-RADS 5 but negative biopsies should be considered for shorter re-screening intervals (1-2 years) to ensure that clinically significant cancers are not missed. Men with a negative MRI, on the other hand, can likely be safely re-

screened at longer intervals (e.g., 4-6 years), optimizing the balance between early detection and overdiagnosis.

This study has several limitations that should be acknowledged. Its retrospective design and reliance on electronic health records introduced potential biases, particularly regarding metastatic status imaging data. This may have influenced the analysis of metastatic spread in the Helsinki cohort. In the HUS cohort, 570 patients with PI-RADS scores of 3 or higher had unknown biopsy status. This may reflect biopsy-related risks, particularly in elderly or comorbid patients, or indicate that biopsies were performed outside our healthcare system. Notably, unknown biopsy status was a significant predictor in the OS model, suggesting that these patients were more likely to die from other causes than prostate cancer, further emphasizing the importance of patient selection in clinical decision-making.

Despite the limitations, our study has several notable strengths. It includes multiple tertiary care centers with equal access to healthcare. It represents the longest follow-up study on PI-RADS v2 published to date. It includes detailed laboratory measurements, treatment data, comorbidities, and cause-specific mortality by linking data to national registries. The use of the Finnish National Cause-of-Death Registry ensured highly accurate and PCSM endpoints.

Future research should focus on integrating AI-based tools into MRI interpretation and risk prediction [37,38]. Deep learning models could potentially MRI-based prostate cancer diagnostics, leading to more standardized and objective assessments beyond PI-RADS scoring.

Conclusions

In this study, we identified PI-RADS v2 score 5 as a robust predictor of PCSM, independent of biopsy GG and metastatic spread. PI-RADS 5 was also strongly associated with OS, MFS, and BCR.

Our findings were validated in both national (Tampere) and international (Lille) cohorts, highlighting the generalizability of PI-RADS as a prognostic imaging marker. Given the typically slow progression of PCa, the identification of a powerful MRI-based prognostic tool underscores the clinical importance of standardizing MRI scoringing. These results reinforce the role of MRI in contemporary prostate cancer risk stratification and management.

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834

2. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-1055. doi:10.1016/j.eururo.2013.12.062

3. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746-757. doi:10.1007/s00330-011-2377-y

4. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - reporting and data system: 2015, version 2. Eur Urol. 2016;69(1):16-40. doi:10.1016/j.eururo.2015.08.052

5. Eldred-Evans D, Tam H, Sokhi H, Padhani AR, Winkler M, Ahmed HU. Rethinking prostate cancer screening: could MRI be an alternative screening test? Nat Rev Urol. 2020;17(9):526-539. doi:10.1038/s41585-020-0356-2

6. Mazzone E, Stabile A, Pellegrino F, et al. Positive predictive value of Prostate Imaging Reporting and Data System version 2 for the detection of clinically significant prostate cancer: A systematic review and meta-analysis. Eur Urol Oncol. 2021;4(5):697-713. doi:10.1016/j.euo.2020.12.004

7. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of Prostate Imaging Reporting and Data System version 2 for detection of prostate cancer: A systematic review and diagnostic meta-analysis. Eur Urol. 2017;72(2):177-188. doi:10.1016/j.eururo.2017.01.042

8. Nam RK, Wallis CJD, Stojcic-Bendavid J, et al. A pilot study to evaluate the role of magnetic resonance imaging for prostate cancer screening in the general population. J Urol. 2016;196(2):361-366. doi:10.1016/j.juro.2016.01.114

9. Manceau C, Beauval JB, Lesourd M, et al. Confirmation by early oncologic outcomes after surgery of the accuracy of intermediate-risk prostate cancer classification based on magnetic resonance imaging staging and targeted biopsy. Eur Urol Open Sci. 2020;21:5-8. doi:10.1016/j.euros.2020.07.003

10. Beksac AT, Cumarasamy S, Falagario U, et al. Multiparametric magnetic resonance imaging features identify aggressive prostate cancer at the phenotypic and transcriptomic level. J Urol. 2018;200(6):1241-1249. doi:10.1016/j.juro.2018.06.041

11. Gandaglia G, Ploussard G, Valerio M, et al. The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol. 2020;77(6):733-741. doi:10.1016/j.eururo.2019.09.005

12. Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate Imaging-reporting and Data System steering committee: PI-RADS v2 status update and future directions. Eur Urol. 2019;75(3):385-396. doi:10.1016/j.eururo.2018.05.035

13. Kohestani K, Månsson M, Arnsrud Godtman R, et al. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial

with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol. 2021;55(2):116-124. doi:10.1080/21681805.2021.1881612

14. Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: The ProScreen randomized trial. JAMA. 2024;331(17):1452-1459. doi:10.1001/jama.2024.3841

15. Nordström T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22(9):1240-1249. doi:10.1016/S1470-2045(21)00348-X

16. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108(8 Pt 2):E171-E178. doi:10.1111/j.1464-410X.2011.10112.x

17. Panebianco V, Barchetti G, Simone G, et al. Negative multiparametric magnetic resonance imaging for prostate cancer: What's next? Eur Urol. 2018;74(1):48-54. doi:10.1016/j.eururo.2018.03.007

18. Pylväläinen J, Hoffström J, Kenttämies A, Auvinen A, Mirtti T, Rannikko A. Risk of clinically significant prostate cancer after a nonsuspicious prostate MRI-A comparison with the general population. Cancer Epidemiol Biomarkers Prev. 2024;33(5):749-756. doi:10.1158/1055-9965.EPI-23-1208

19. Shin TJ, Jung W, Ha JY, Kim BH, Kim YH. The significance of the visible tumor on preoperative magnetic resonance imaging in localized prostate cancer. Prostate Int. 2021;9(1):6-11. doi:10.1016/j.prnil.2020.06.001

20. Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045-1053. doi:10.1016/j.eururo.2015.01.013

21. Klotz L. The genomics and natural history of MRI-visible vs MRI-invisible prostate cancers: Clinical implications. J Urol. 2024;212(3):494-498. doi:10.1097/JU.0000000000004069

22. Lehto TPK, Pylväläinen J, Sandeman K, et al. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis. Int J Cancer. 2024;154(5):926-939. doi:10.1002/ijc.34743

23. Fiard G, Seigneurin A, Roumiguié M, et al. Prognostic significance of PI-RADS 5 lesions in patients treated by radical prostatectomy. World J Urol. 2023;41(5):1285-1291. doi:10.1007/s00345-023-04371-6

24. Wibmer AG, Lefkowitz RA, Lakhman Y, et al. MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clin Genitourin Cancer. 2022;20(4):319-325. doi:10.1016/j.clgc.2022.04.001

25. Reijnen JS, Marthinsen JB, Tysland AO, et al. Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital. Abdom Radiol (NY). 2021;46(12):5639-5646. doi:10.1007/s00261-021-03249-8

26. Stabile A, Mazzone E, Cirulli GO, et al. Association between multiparametric magnetic resonance imaging of the prostate and oncological outcomes after primary treatment for prostate cancer: A systematic review and meta-analysis. Eur Urol Oncol. 2021;4(4):519-528. doi:10.1016/j.euo.2020.11.008

27. Rajwa P, Mori K, Huebner NA, et al. The prognostic association of prostate MRI PI-RADSTM v2 assessment category and risk of biochemical recurrence after definitive local therapy for prostate cancer: A systematic review and meta-analysis. J Urol. 2021;206(3):507-516. doi:10.1097/JU.0000000000001821

28. Kim R, Kim CK, Park JJ, et al. Prognostic significance for long-term outcomes following radical prostatectomy in men with prostate cancer: Evaluation with Prostate Imaging Reporting and Data System version 2. Korean J Radiol. 2019;20(2):256-264. doi:10.3348/kjr.2018.0613

29. Pylväläinen J, Hoffström J, Kenttämies A, Auvinen A, Mirtti T, Rannikko A. Abstract 2234: Incidence of clinically significant prostate cancer after negative prostate MRI - comparison to general population. Cancer Res. 2022;82(12_Supplement):2234-2234. doi:10.1158/1538-7445.am2022-2234

30. Wibmer AG, Chaim J, Lakhman Y, et al. Oncologic outcomes after localized prostate cancer treatment: Associations with pretreatment prostate magnetic resonance imaging findings. J Urol. 2021;205(4):1055-1062. doi:10.1097/JU.0000000000001474

31. Mäkinen T, Karhunen P, Aro J, Lahtela J, Määttänen L, Auvinen A. Assessment of causes of death in a prostate cancer screening trial. Int J Cancer. 2008;122(2):413-417. doi:10.1002/ijc.23126

32. Bommelaere T, Villers A, Puech P, et al. Risk estimation of metastatic recurrence after prostatectomy: A model using preoperative magnetic resonance imaging and targeted biopsy. Eur Urol Open Sci. 2022;41:24-34. doi:10.1016/j.euros.2022.04.011

33. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations inR. J Stat Softw. 2011;45(3). doi:10.18637/jss.v045.i03

34. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. J Urol. 1999;161(4):1390-1390. doi:10.1016/s0022-5347(01)61695-1

35. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122

36. Peyrottes A, Baboudjian M, Diamand R, et al. Are patients with Prostate Imaging Reporting and Data System 5 lesions eligible for active surveillance? A multicentric European study. Eur Urol Oncol. Published online February 17, 2025. doi:10.1016/j.euo.2025.01.008

37. Saha A, Bosma JS, Twilt JJ, et al. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024;25(7):879-887. doi:10.1016/S1470-2045(24)00220-1

38. Turkbey B. AI in prostate MRI: enhancing accuracy and reducing overdiagnosis. Nat Rev Urol. Published online September 11, 2024. doi:10.1038/s41585-024-00940-5

Tables

Table 1: Patient demographics for the cohorts. Count data is shown as patient amounts (percentage inside column) and numeric data as median (IQR).

	Cohort	Helsinki	Tampere	Lille
	N	4674	1474	301
	Age at MRI (years)	68 (61 - 73)	67 (62 - 72)	68 (64 - 84)
	Follow-up (years)	5.0 (4.2 - 5.8)	2.21 (1.11 - 3.44)	6.2 (4.8 - 7.4)
	Pre-MRI PSA	7.8 (5.1 - 11.7)	7.0 (5.0 - 11.0)	6.9 (5.3 - 10.0)
Negative MRI	**PI-RADS score 0**	1555 (33%)	-	-
	PI-RADS score 1	7 (0%)	81 (6%)	-
	PI-RADS score 2	51 (1%)	191 (13%)	14 (5%)
Positive MRI	**PI-RADS score 3**	718 (15%)	224 (15%)	43 (14%)
	PI-RADS score 4	928 (20%)	607 (41%)	96 (32%)
	PI-RADS score 5	1415 (30%)	371 (25%)	148 (49%)
Biopsy	**Benign**	831 (18%)	-	-
	GG 1	375 (8%)	511 (35%)	62 (21%)
	GG 2/3 [a]	-	23 (2%)	-
	GG 2	726 (16%)	400 (27%)	132 (44%)
	GG 3	519 (11%)	154 (10%)	86 (29%)
	GG 4	214 (5%)	97 (7%)	15 (5%)
	GG 5	311 (7%)	166 (11%)	6 (2%)
	No biopsy or unknown	1698 (36%)	123 (8%)	-
CCI	**0**	3638 (78%)	-	-
	1-3	871 (19%)	-	-
	4+	160 (3%)	-	-
Interventions	**No known interventions or only non-curative treatments**	2671 (57%)	526 (36%)	-
	RP	706 (15%)	324 (22%)	301 (100 %)
	RT	1053 (23%)	573 (39%)	-
	RP + RT	244 (5%)	51 (3%)	-
Event type	**Censoring**	4216 (90%)	1444 (98%)	275 (91%)
	Non-PCa death	374 (8%)	-	24 (8%)
	PCa death	84 (2%)	-	2 (1%)
	Any death (PCa or Non-PCa)	-	30 (2%)	-

CCI: CCI: (adjusted) Charlson's Comorbidity Index
GG: ISUP Grade Group
RT: Radiation Therapy
RP: Radical Prostatectomy
[a:] For some registry data, only Gleason sum 7 information was available

Table 2: Patient demographics in PI-RADS version 2 era in HUS, with stratification to negative MRI findings (PI-RADS 0 to 2), PI-RADS score 3 to 4, and PI-RADS score 5. Count data is shown as patient amounts (percentage inside column) and numeric data as median (IQR).

		All PI-RADS	Negative MRI	PI-RADS 3 & 4	PI-RADS 5
	N	4674	1613	1646	1415
	Age at MRI (years)	68 (61 - 73)	65 (59 - 71)	68 (62 - 73)	70 (64 - 75)
	Follow-up (years)	5.0 (4.2 - 5.8)	4.8 (4.1 - 5.6)	5.1 (4.2 - 6.0)	5.0 (4.1 - 6.0)
	Pre-MRI PSA (µg/L)	7.8 (5.1 - 11.7)	6.6 (4.0 - 9.7)	7.3 (5.0 - 10.1)	10.3 (7.2 - 17.6)
Biopsy	**Benign**	831 (18%)	349 (22%)	399 (24%)	83 (6%)
	GG 1	375 (8%)	53 (3%)	231 (14%)	91 (6%)
	GG 2	726 (16%)	53 (3%)	362 (22%)	311 (22%)
	GG 3	519 (11%)	19 (1%)	190 (12%)	310 (22%)
	GG 4	214 (5%)	5 (0%)	71 (4%)	138 (10%)
	GG 5	311 (7%)	6 (0%)	64 (4%)	241 (17%)
	No biopsy or unknown	1698 (36%)	1128 (70%)	329 (20%)	241 (17%)
CCI	**0**	3922 (77%)	1262 (78%)	1320 (80%)	1056 (75%)
	1-3	981 (19%)	312 (19%)	291 (18%)	268 (19%)
	4+	205 (4%)	35 (2%)	34 (2%)	91 (6%)
Interventions	**No known interventions or only non-curative treatments**	2671 (57%)	1509 (94%)	890 (54%)	272 (19%)
	RP	706 (15%)	56 (3%)	327 (20%)	323 (23%)
	RT	1053 (23%)	41 (3%)	343 (21%)	669 (47%)
	RP + RT	244 (5%)	7 (0%)	86 (5%)	151 (11%)
Event type	**Censoring**	4216 (90%)	1519 (94%)	1513 (92%)	1184 (84%)
	Non-PCa death	374 (8%)	93 (6%)	129 (8%)	152 (11%)
	PCa death	84 (2%)	1 (0%)	4 (0%)	79 (6%)

CCI: (adjusted) Charlson's Comorbidity Index
GG: ISUP Grade Group
RT: Radiation Therapy
RP: Radical Prostatectomy

Figures



Figure 1: A) Schematic overview of patient cohort composition in Helsinki, Tampere, and Lille; Kaplan-Meier curves and numbers at risk with events for B) Helsinki cohort PCSM, OS for patients with PCa diagnosis, and MFS; C) Tampere cohort OS for in-hospital death; and D) Lille cohort BCR / Relapse Free Survival and MFS. Reported p-values are log-rank tests.



Figure 2: Patient proportions during follow-up for competing risks with alive, censored, non-PCa death and PCa-specific mortality shown as a function of time in HUS cohort.



Figure 3: Multivariable Cox model forest plot in PI-RADS version 2 era with hazard ratios (95% CI) for (A) PCa-specific mortality; (B) Overall Survival; (C) PCa-specific mortality for combining PI-RADS and patients' metastatic status at the time of diagnostic MRI.